Reference Articles

A GROWING BODY OF EVIDENCE IN SUPPORT OF VICRYL* PLUS

Evidence of Efficacy

• In Vitro Antibacterial Evaluation of Coated VICRYL* Plus Antibacterial Suture (coated polyglacin 910 with triclosan) Using Zone of Inhibition Assays. Surg Infect J. 2002;3 (suppl 1):S79-S87.—Rothenburger S, Spangler D, Bhende S, Burkley D.
• Chemistry and Safety of Triclosan and Its Use as an Antibacterial Coating on Coated VICRYL* Plus Antibacterial Suture (coated polyglactin 910 with triclosan). Surg Infect J. 2002;3 (suppl 1): S45-S54.—Barbolt TA.
• Experimental Efficacy Study of Coated VICRYL* Plus Antibacterial Suture in Guinea Pigs Challenged with Staphylococcus aureus.—Storch M, Rothenburger S, Jacinto G.

Comparison to VICRYL* Plus Antibacterial Suture (coated polyglactin 910 with Triclosan)

• Physical and Functional Comparison of Coated VICRYL* Plus Antibacterial Suture (coated polyglactin 910 with triclosan) With Coated Vicryl* Suture (coated polyglacin 910). Surg Infect J. 2002;3 (suppl 1): S65-S77.—Storch M, Scalzo H, Jacinto G.
• A 28-Day Study of the Effect of Coated VICRYL* Plus Antibacterial Suture (coated polyglacin 910 with triclosan) on Wound Healing in Guinea Pig Linear Incisional Skin Wounds. Surg Infect J. 2002;3 (suppl1):S89-S98.—Storch M, Perry LC, Davidson JM, Ward JJ.

Small Animal Surgical Site Infection

• Surgical Wound Infection Rates in Dogs and Cats Data from a Teaching Hospital. Veterinary Surgery, 1988, 17:60-64,—Vasseur P, Levy J, Dowd E, Eliot J.
• Epidemiologic Evaluation of Postoperative Wound Infections in Dogs and Cats. JAVMA 1997, Vol 210, No. 9: 1302-1306.— Brown DC, Conzemius MG, Shofer F, Swann H.
• The Effects of Perioperative Hypothermia and the Duration of Anesthesia on Postoperative Wound Infection Rate in Clean Wounds: A Retrospective Study. Veterinary Surgery 2000, 29:123-127.—Beal MW, Brown DC, Shofer F.
• Suture Reaction Following Extra-articular Stifle Stabilization in the Dog—Part I & II: A Retrospective Study of 161 Stifles. JAAHA 1981, Vol 17, 569:574—Dulisch ML.

Equine Surgical Site Infection

• Risk Factors for Wound Infection Following Celiotomy in Horses. JAVMA 1997, Vol 210, No. 1:78- 81.—Honnas CM, Cohen ND
• An Examination of the Occurance of Surgical Wound Infection Following Equine Orthopaedic Surgery (1981-1990). Equine vet J. (1994) 26 (4) 323-326.—Macdonald DG, Morley PS, Bailey JV, Barber SM, Fretz PB.
• Isolation of Methicillin-Resistant Staphylococcus aureus from a Postoperative Wound Infection in a Horse. JAVMA 1997, Vol 211, No. 5:590-592.—Hartmann FA, Trostle SS, Klohnen AAO.

 

New VICRYL* Plus Antibacterial Suture Evidence of Efficacy

Preclinical Study #1
In Vitro Antibacterial Evaluation of Coated VICRYL* Plus Antibacterial Suture (coated polyglactin 910 with triclosan) Using Zone of Inhibition Assays. Surg Infect J. 2002;3 (suppl 1):S79-S87. —Rothenburger S, Spangler D, Bhende S, Burkley D.

Summary Statement
In vitro preclinical studies have demonstrated that VICRYL* Plus Antibacterial suture effectively inhibits the growth of Staphylococcus aureus, Staphylococcus epidermidis, methicillin-resistant Staphylococcus aureus (MRSA), and methicillin-resistant Staphylococcus epidermidis (MRSE).

Conclusions

• Coated polyglactin 910 with triclosan suture creates a zone of inhibition
• The zone of inhibition is effective against Staphylococcus aureus, Staphylococcus epidermidis, methicillin-resistant S aureus, and methicillin-resistant S epidermidis
• IRGACARE MP* concentration remains effective after multiple in vivo tissue passes

 

Preclinical Study #2
Chemistry and Safety of Triclosan and Its Use as an Antibacterial Coating on Coated VICRYL* Plus Antibacterial Suture (coated polyglactin 910 with Triclosan). Surg Infect J. 2002;3 (suppl 1):S45-S54. —Barbolt TA.

Summary Statement
Triclosan has been used effectively for over 30 years in humans. The safety of IRGACARE MP* as the active agent in VICRYL* Plus Antibacterial suture has been well evaluated and confirmed.

Conclusions

• Triclosan has been used effectively in personal care products for over 30 years IRGACARE MP* coated suture was found to be nontoxic, nonirritating, noncarcinogenic, nonteratogenic, and not a chemical pyrogen
• Tissue reaction, healing response, and absorption profile of VICRYL* Plus Antibacterial suture was not affected by the presence of IRGACARE MP*

 

Preclinical Study #3
Physical and Functional Comparison of Coated VICRYL* Plus Antibacterial Suture (coated polyglactin 910 with triclosan) With Coated VICRYL* Suture (coated polyglactin 910). Surg Infect J. 2002;3 (suppl 1):S65-S77. —Storch M, Scalzo H, Jacinto G.

Summary Statement
VICRYL* Plus Antibacterial suture has the same dependable construction as VICRYL* suture. Blind testing in vivo by surgeons demonstrated the same excellence in performance and handling.

Conclusions

• VICRYL* Plus Antibacterial suture has the same performance and handling as VICRYL* suture, the world's #1 suture, with the added benefit of antibacterial activity
• Surgeons found VICRYL* Plus Antibacterial suture to be indistinguishable from VICRYL* suture in terms of ease of passage through tissue, first throw knot holding, knot tie-down smoothness, knot security, surgical handling, and overall performance
• There were no observed differences in breaking strength and absorption rates between the two sutures

 

Preclinical Study #4
A 28-Day Study of the Effect of Coated VICRYL* Plus Antibacterial Suture (coated polyglactin 910 with triclosan) on Wound Healing in Guinea Pig Linear Incisional Skin Wounds. Surg Infect J. 2002;3(suppl 1):S89-S98. —Storch M, Perry LC, Davidson JM, Ward JJ.

Summary Statement
VICRYL* Plus Antibacterial suture demonstrated no significant difference from VICRYL* suture in wound healing response (P <.05).

Conclusions

• In vivo animal test results demonstrated VICRYL* Plus Antibacterial suture to have no compromising effect on the wound healing process
• In vivo test results demonstrated no significant difference in bursting strength between VICRYL* Plus Antibacterial suture and VICRYL* suture